---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-010954"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T07:41:33.629571+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phibro Animal Health appoints Glenn C. David as CFO effective Feb 9, 2024

## Summary
- Glenn C. David, former Zoetis CFO and group president, joins Phibro as CFO starting Feb 9, 2024.
- David receives $650K base salary, 50% target bonus, $135K signing bonus, and 300K RSUs (half time-vesting, half performance-vesting).
- Performance RSUs vest based on 90-day average stock price from $20 to $60+ over 5 years.
- Interim CFO Richard Johnson will stay in advisory role for smooth transition.

## SEC filing metadata
- accession: 0001104659-24-010954
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/tm245238d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-010954
- JSON: https://secwatch.observer/filing/0001104659-24-010954.json
- Plain text: https://secwatch.observer/filing/0001104659-24-010954.txt

## Key facts
- Executive change
  Glenn C. David was appointed as Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm
- Executive change
  Richard Johnson changed role as interim Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.
  - Action: stepped down as interim CFO
  - Role: interim Chief Financial Officer
  source text: Mr. Richard Johnson, who has served as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.